Track topics on Twitter Track topics that are important to you
If there was a company that needed a series of good news stories this week, it was AstraZeneca. The blow of the Mystic trial was enough to have the company seeing stars, and its share value seeing the depths, but it has recovered slightly in the last few days with breakthrough designations, and a Priority Review for its drug, acalabrutinib.
Original Article: AstraZeneca's Priority Review good news provides reprieveNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...